Lexeo (LXEO) Officer Sells Shares to Cover RSU Taxes; 60,372 Owned

Rhea-AI Filing Summary

Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics (LXEO), reported a sale of 2,848 shares of common stock on 08/18/2025 at a price of $4.668 per share to cover tax obligations arising from the release of restricted stock units (RSUs). After the reported transaction, he beneficially owns 60,372 shares, which include 49,687 RSUs. The filing identifies the transaction as a sale to cover taxes on RSU vesting and was submitted under a single reporting person designation. The form is signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Transparent disclosure of a tax-covering sale tied to RSU vesting
• Significant retained beneficial ownership of 60,372 shares after the sale

Negative

• Reduction in free-trading shares by 2,848 shares due to the sale

Insights

Securities Analyst

TL;DR: Routine insider sale to cover RSU taxes; ownership remains meaningful at 60,372 shares.

The reported sale of 2,848 shares at $4.668 per share is described as a tax-withholding sale tied to RSU vesting, which is a common source of insider dispositions and typically viewed as non-discretionary. Post-transaction beneficial ownership of 60,372 shares (including 49,687 RSUs) indicates continued alignment with shareholders, though the disclosure does reduce the officer's direct free-trading shares by the reported amount. There is no indication of additional derivative transactions or planned sales in this Form 4.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure; sale documented as tax-covering from RSU issuance.

The Form 4 documents a transparent, routine disposition tied explicitly to tax obligations on RSU release. The filing identifies the reporting person as an officer (Chief Technical Officer) and uses a single reporting-person filing. From a governance standpoint, the form meets Section 16 reporting expectations: it specifies the transaction code, quantity, price, and the nature of the sale. No red flags such as unexplained transfers, loans, or derivative activity appear in this disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S(1)		2,848	D	$4.668	60,372(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. Includes 49,687 RSUs.

	/s/ Youjin Choi, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Jose Manuel Otero report on Form 4 for LXEO?

He reported a sale of 2,848 common shares on 08/18/2025 at $4.668 per share.

Why were shares sold by the LXEO reporting person?

The sale was executed to cover tax obligations arising from the release of restricted stock units (RSUs).

How many shares does the LXEO reporting person beneficially own after the transaction?

He beneficially owns 60,372 shares following the reported transaction, which includes 49,687 RSUs.

What is the reporting person’s role at Lexeo Therapeutics (LXEO)?

The reporting person is listed as an Officer with the title Chief Technical Officer.

Does the Form 4 show any derivative transactions for the reporting person?

No. Table II for derivative securities shows no reported derivative transactions in this filing.